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The neurodegenerative disorder multiple system atrophy (MSA) is characterized by
autonomic failure, cerebellar ataxia and parkinsonism in any combination associated
with predominantly oligodendroglial α-synuclein (α-syn) aggregates (glial cytoplasmic
inclusions = GCIs). To date, there is no effective disease modifying therapy.
Previous experiments have shown that the aggregation inhibitor anle138b reduces
neurodegeneration, as well as behavioral deficits in both transgenic and toxin mouse
models of Parkinson’s disease (PD). Here we analyzed whether anle138b improvesmotor
skills and reduces neuronal loss, as well as oligodendroglial α-syn aggregation in the
PLP-α-syn transgenic mouse challenged with the mitochondrial toxin 3-nitropropionic
acid (3-NP) to model full-blown MSA. Following 1 month of treatment with anle138b,
MSA mice showed signs of motor improvement affecting stride length, but not pole, grip
strength, and beam test performance. Loss of dopaminergic nigral neurons and Purkinje
cells was not attenuated and GCI density remained unchanged. These data suggest that
the pathology in transgenic PLP-α-syn mice receiving 3-NP might be too advanced to
detect significant effects of anle138b treatment on neuronal loss and intracytoplasmic
α-syn inclusion bodies. However, the partial motor amelioration may indicate potential
efficacy of anle138b treatment that may be mediated by its actions on α-syn oligomers
or may reflect improvement of neuronal dysfunction in neural at risk populations. Further
studies are required to address the efficacy of anle138b in transgenic α-syn models of
early-stage MSA and in the absence of additional toxin application.
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INTRODUCTION
Multiple system atrophy (MSA) is a progressive, adult-onset neurodegenerative disorder that
belongs to the spectrum of α-synucleinopathies (ASP). MSA patients present with parkinsonism,
cerebellar, autonomic, and pyramidal dysfunction in any combination (Fanciulli and Wenning,
2015). Currently, no treatment options are available to stop the progression of this fatal disease,
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only the amelioration of symptoms is feasible (Eschlbock et al.,
2016). Two major types of MSA are distinguished: striatonigral
degeneration (SND) underlies the parkinsonian variant of MSA
whereas olivopontocerebellar atrophy (OPCA) is associated with
the cerebellar subtype. In end-stage disease usually both SND
and OPCA are present. In MSA α-synuclein (α-syn) accumulates
in oligodendrocytes (glial cytoplasmic inclusions = GCIs or
Papp-Lantos bodies). However, α-syn-positive inclusions may
appear in neurons (Cykowski et al., 2015) as well and sometimes
also in astroglial cells similar to other ASP, such as Parkinson’s
disease (PD) and dementia with Lewy bodies (DLB). The
various inclusions appear to contribute to the neurodegeneration
associated with MSA (Wenning et al., 2008). More recent
evidence suggests that toxic α-syn aggregates might induce a
prion-like spreading in MSA and related ASP (Angot et al., 2010;
Reyes et al., 2014; Prusiner et al., 2015).
In previous work we have replicated MSA-like glial inclusions
and mild SND in mice overexpressing human α-syn (hα-
syn) under the control of the proteolipid protein (PLP)
promoter (Kahle et al., 2002; Stefanova et al., 2005; Fellner
et al., 2015; Stefanova and Wenning, 2015). In this PLP-α-
syn mouse model, additional chronic oxidative stress induced
by intraperitoneal (IP) 3-nitropropionic acid (3-NP) injections
led to full-blown MSA-like pathology including widespread
insoluble α-syn aggregates in oligodendroglia associated with
SND and OPCA, as well as profound microglial and astroglial
activation. Moreover, the oxidative stress in PLP-α-syn mice
resulted in enhanced motor deficits (Stefanova et al., 2005;
Stefanova and Wenning, 2015). Because of the subacute time
course and because of the similarities of pathological and
behavioral deficits reported in the PLP-α-synmice treated with 3-
NP and human clinically overt MSA, this mouse model provides
a useful test bed to investigate new therapeutic drugs and to
transfer positive candidates to clinical trials (Kuzdas-Wood et al.,
2014). Therefore, we sought to investigate the disease-modifying
properties of the aggregation inhibitor, anle138b, in PLP-α-syn
mice treated with 3-NP. In a recent study anle138b was shown
to bind structure-dependently to pathological aggregates and
furthermore to inhibit the formation of pathological oligomers,
including α-syn, in vitro and in vivo (Wagner et al., 2013,
2015). Moreover, Wagner and colleagues reported an inhibition
of aggregate formation, neuronal degeneration and disease
progression in different mouse models of PD without detectable
toxicity at therapeutic doses (Wagner et al., 2013; Levin et al.,
2014). For the first time we here investigate the effects of anle138b
in a MSA mouse model combining overexpression of α-syn in
oligodendrocytes and chronic oxidative stress caused by 3-NP
injections.
MATERIALS AND METHODS
Animals and Treatments
All animal experiments were performed according to ethical
guidelines and Austrian law as well as with permission from
the Federal Ministry of Science and Research, Austria. All
efforts were made to reduce the number of animals used and
minimize their suffering. All mice were bred and maintained
under temperature-controlled, pathogen free conditions, and 12-
h light/dark cycle granting free access to water and food at
the Animal Facility of Medical University Innsbruck. In the
present study a total of 28 homozygous transgenic PLP-α-syn
mice, obtained from Prof. Philipp Kahle (Tübingen, Germany)
and described previously (Kahle et al., 2001), were used. All
mice were genotyped applying tail clip and PCR for hα-syn
using following primers with a product size of 450 bp: fwd:
5′-ATG GAT GTA TTC ATG AAA GG-3′; rev: 5′-TTA GGC
TTCAGGTTCGTAG-3′. Determination of oligodendroglial AS
overexpression was previously reported in the PLP-α-syn mice
using immunofluorescence (Kahle et al., 2001; Stemberger et al.,
2010).
Twelve month old homozygous transgenic PLP-α-syn mice
were randomized into two treatment groups receiving either
vehicle or aggregation inhibitor anle138b [3-(1,3-benzodioxol-
5-yl)-5-(3-bromophenyl)-1H-pyrazole] treatment. The anle138b
group started receiving food pellets (Ssniff, Soest, Germany)
that contained the compound anle138b (2 g compound/1 kg
food) whereas the control group received food pellets without
the compound anle138b 1 week prior to 3-NP intoxication.
Body weight of the mice was controlled daily. Food pellets were
provided throughout the whole experiment. After 1 week both
groups were intoxicated with 3-NP to induce the full-blown
pathology similar to human disease (Stefanova et al., 2005). The
3-NP IP treatment was accomplished using following scheme as
described previously: 4×10, 4×20, 4×40, 4×50mg/kg (injection
volume 200µL; Stefanova et al., 2005). 3-NP was dissolved in
saline and pH was adjusted to 7.4 using 1 mol/L sodiumhydroxid
(NaOH). During the intoxication period IP injections of 3-NP
were conducted every 12 h. From day 5 of the intoxication period
till the end of the experiment parallel to the delivery of anle138b
with the food, mice received 250mg/kg b. w. anle138b by oral
gavage (Unimed, Switzerland) twice a day. This was done to avoid
any decrease in anle138b dosing due to disability and reduced
food intake after the 3-NP intoxication. Control mice received
vehicle by oral gavage according to the same time schedule.
Behavioral assessment was performed following oral treatment
starting with day 22 and mice were sacrificed 4 weeks after
starting treatment with food pellets according to the following
protocols.
Behavioral Tests
All behavioral tests were performed by a researcher who was
blinded to the treatment status of the animals.
Standardized Motor Behavioral Scale
Motor score analysis to assess the severity of 3-NP induced
motor disability of the treated transgenic PLP-α-syn mice was
performed every day beginning with the first IP 3-NP injection.
To estimate hindlimb clasping, general locomotor activity,
hindlimb dystonia, truncal dystonia, and postural challenge
response a previously described rating scale was applied (0,
normal; 1, slightly disturbed; 2, markedly disabled; Fernagut
et al., 2002; Stefanova et al., 2005). For each motor score analysis
per day a total score was calculated.
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Open Field Activity
The Flex Field Activity System (San Diego Instruments,
USA) was used to assess the locomotor activity of the mice
upon treatment as previously described (Stefanova et al.,
2012). Thereby, 544 photo-beam channels monitor and count
horizontal and vertical locomotor activity of the mice that were
placed in the center of the open field (40.5 × 40.5 × 36.5 cm)
for a period of 15min. The tests were performed in a dark room
isolated from external noises and light during the test period. The
total counts in the horizontal and vertical (rearing) activity were
further analyzed.
Stride Length Analysis
To test the stride length of the mice after treatment the
DigiGaitTMAnalysis System (Mouse Specifics, USA) was used as
described elsewhere (Amende et al., 2005; Stefanova et al., 2012).
Briefly, mice were put onmotor-driven transparent treadmill belt
with a high-speed digital video camera placed below the belt
which captured the gait of the mice (speed 25 cm/s). The specific
DigiGait Software 9.0 (Mouse Specific, USA) was used to analyze
the collected images and evaluate the mean stride length of each
forelimb and hindlimb of the mice.
Pole Test
The pole test has been described as a helpful behavioral test
for evaluating movement disorders caused by striatal dopamine
depletion (Matsuura et al., 1997; Fernagut et al., 2002). Each
mouse was trained and accustomed to the test 1 day before. For
the test a wooden vertical pole with rough surface, 1 cm wide
and 50 cm high was used. The mice were placed with the head
up at the top of the pole and the time for turning downwards
(Tturn) and the total time for climbing down the pole until the
mice reached the floor with all four paws (Ttotal) was measured in
five attempts. For statistical analysis only the best performance of
the five trials was used (Fernagut et al., 2002). For mice that were
unable to successfully complete the test a default value of 120 s
was taken into account (Stefanova et al., 2005).
Beam Walking Test
Fine motor coordination and balance capacities of the mouse
were assessed employing the beam walking test (Luong et al.,
2011). Thereby, the mice have to traverse 50 cm of length on a
horizontal wooden beam (width 0.9 cm). The day before the test
mice were trained to get accustomed to the task. The time for
traversing the beam and the number of slips were evaluated in
five consecutive attempts. Again the best performance of the five
trials of each mouse was used for statistical analysis.
Grip Strength Analysis
To measure forelimb grip strength of mice upon 3-NP injection,
the ability to remain clinging to an inverted wire grid for up to
1min under constant mild shaking was tested in three trials. The
best performance was used for statistical analysis.
Tissue Processing
On day 28 after starting the anle138b treatment, animals were
perfused under deep thiopental anesthesia (12 mg/100 g body
weight, IP) using phosphate buffered saline (PBS; 25mM, 0.9%
NaCl, pH 7.4) followed by 4% paraformaldehyde (pH 7.4, Sigma-
Aldrich, Austria). After removing brains quickly, they were post-
fixed in 4% PFA over night at 4◦C, and then kept in 30%
sucrose (Sigma-Aldrich, Austria) solution until they sank at 4◦C.
Afterwards, brains were frozen using 2-methylbutan and stored
at -80◦C until further processing. Whole brains were cut on
a freezing microtome (Leica, Nussloch, Germany) processing
40µm thick sections, whereby one section was collected on slides
and six sections were kept free-floating and either dried or kept
in assorter buffer.
Immunohistochemistry for Light
Microscopy
Immunohistochemical staining was performed according to a
standard immunoperoxidase protocol for free-floating sections
using following antibodies: mouse anti-dopamine- and cAMP-
regulated phosphoprotein (DARPP-32; 1:5000; BD Biosciences,
USA), mouse monoclonal anti-tyrosine hydroxylase (TH; 1:1000;
Sigma, USA), rat anti-human α-syn (aa 116-131 hα-syn; dilution
and company please; 15G7, Enzo Life Sciences, Germany),
rabbit anti-phosphorylated α-syn (pα-syn; 1:1000; Abcam, UK),
and mouse anti-nitrated α-syn (nα-syn; 1:1000; Invitrogen,
Zymed Laboratories, USA). In case of the visualization of
partially proteinase-K (PK)-resistant human α-syn aggregates,
tissue slices were pre-stained with haematoxylin and digested
with PK before the incubation with antibodies against α-
syn (Neumann et al., 2004). Biotinylated horse anti-mouse
IgG, biotinylated goat anti-rat IgG, and biotinylated goat
anti-rabbit IgG (1:200; Vector Laboratories, USA) were used
as secondary antibodies. Vectastain ABC reagent (Vector
Laboratories, USA) and 3,3′-diaminobenzidine were applied
to visualize the immunohistochemical binding sites. Stained
sections were mounted onto gelatin-coated slides, dehydrated
and coverslipped with Entellan.
Image Analyses
Stereological analysis was performed by an unbiased investigator
at the Nikon E-800 microscope equipped with Nikon
digital camera DXM 1200 and Stereoinvestigator Software
(MicroBrightField Europe e.K., Germany) as described
previously (Mayhew and Gundersen, 1996; Stefanova et al.,
2012). For the estimation of the number of dopaminergic
neurons in substantia nigra pars compacta (SNc) the optical
fractionator was applied. The number of DARPP-32-stained
Purkinje cells was estimated in a region outlined to include
only the Purkinje cell layer, and the number of PK-resistant
GCIs per mm2 was estimated in the SNc, SN reticulata (SNr),
stratum purkinjense, and stratum granulosum of the cerebellar
cortex (German et al., 2001; Stefanova et al., 2012). Furthermore,
the percentage of nα-syn- and pα-syn-positive inclusions was
analyzed by determining mean gray values of the nα-syn and
pα-syn immunoreactivity in the same regions as mentioned for
the estimation of the PK-resistant GCIs at constant acquisition
camera settings with values of 0 for black and 256 for white. The
optical density was measured after the transformation of mean
gray values by using the formula OD=−log (mean gray/256) as
previously described (Stefanova et al., 2012).
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Statistical Analyses
All statistical analyses were conducted using the software Graph-
Pad Prism 5 (Graphpad Software, San Diego, CA). The mean
± S.E.M was used to present the results. Unpaired t-test was
used for the comparison of the behavioral performance of the
two groups, if not indicated otherwise. A P-value <0.05 was
considered statistically significant.
RESULTS
Anle138b Treatment Induces Mild Motor
Improvement in the PLP-α-syn Mice
Challenged with 3-NP
Body weight of vehicle and anle138b treated PLP-α-syn mice was
monitored throughout the experiment. No significant differences
in body weight between the groups were detected throughout
the study. Upon IP injections of 3-NP a typical reduction of
body weight was measured with the lowest recordings at the end
of 3-NP administration. After day 16 a mild increase followed
by a stabilization of the body weight was observed (Figure 1A).
Moreover, starting with 3-NP administration the motor score
of vehicle- and anle138b-treated mice was assessed using the
Standardized Motor Behavioral Scale described by Fernagut et al.
(2002). As expected the motor score increased in both groups
upon 3-NP injections with the highest scores at the end of
3-NP administration. The termination of 3-NP injections was
followed by slight improvement of the motor score that stayed
stable until the end of the experiment. We did not observe any
statistically significant difference in the motor score at any time
point regarding the two treatment groups (Figure 1B).
General locomotor activity in the vertical (rearing) and
horizontal plane in an open field arena showed no significant
differences between vehicle- and anle138b-treated PLP-α-syn
mice (Figures 2A,B). However, analysis of the stride length
revealed a significantly reduced variability of the stride length
coefficient of variation (CV) in hindlimbs of anle138b treated
mice compared to the vehicle group (Figure 2C). Assessment
of the grip strength revealed that anle138b-treated PLP-α-syn
mice were able to perform the test for a while longer compared
to vehicle-treated mice. Yet, no statistical significance was
reached regarding this test (Figure 2D). Furthermore, we found
a numeric reduction of beam walking time (Figure 3A) and slips
(Figure 3B) in the beam walking test, as well as a decreased T-
total (Figure 3C) and T-turn (Figure 3D) time in the pole test
when comparing anle138b with vehicle-treated animals, but none
of these parameters reached statistically significant change due to
the treatment with anle138b.
Anle138b Does Not Rescue Dopaminergic
and Purkinje Neurons In 3-NP-Treated
PLP-α-syn Mice
Loss of TH-immunoreactive neurons in SNc was induced by
systemic treatment with 3-NP in PLP-α-syn mice as shown by
the low total number of stereologically estimated TH-positive
neurons (Figure 4A) compared to TH numbers in PLP-α-syn
mice as previously shown (Stefanova et al., 2005). Administration
FIGURE 1 | Effects of anle138b on body weight and motor score. (A)
Body weight was comparable in anle138b- and vehicle-treated PLP-α-syn
mice. A decrease of body weight was observed in both groups upon
intraperitoneal 3-NP injections (day 8–15), yet body weight increased after
3-NP injections again and remained steady. (B) Motor score evaluation of the
treated animals was performed daily. Thereby, for the evaluation of hindlimb
clasping, general locomotor activity, hindlimb dystonia, truncal dystonia, and
postural challenge response a previously described rating scale was applied
(0, normal; 1, slight disturbed; 2, markedly disabled). The total motor score per
day increased permanently with highest scores on day 16. Termination of 3-NP
injections led to a slight improvement of the motor score in both treatment
groups. No significant differences were detected between mice treated with
vehicle or anle138b. Data are presented as mean ± SEM. PLP-α-syn mice
treated with vehicle n = 10, treated with anle138b n = 8. Data were analyzed
by two-way repeated measures ANOVA with post-hoc Bonferroni’s test.
of the aggregation inhibitor anle138b did not show protection
of dopaminergic neurons in SNc compared to vehicle treated
mice (Figure 4A). Furthermore, a reduction of Purkinje cells was
induced by the 3-NP treatment as indicated by the low number
of Purkinje cells per mm3 (Figure 4B) compared to Purkinje
cell numbers in PLP-α-syn mice as previously shown (Stefanova
et al., 2005). Anle138b-treatedmice showed no significant change
regarding the numbers of Purkinje neurons as compared to
vehicle-treated mice (Figure 4B).
PLP-α-syn Mice Treated with Anle138b Do
Not Present with a Reduced Number of
α-syn-Positive Inclusions
Oral treatment with the compound anle138b had no significant
effect on the number of PK-resistant GCIs in any of the regions
studied as compared to vehicle-treated mice. Independent of the
anle138b treatment, region-specific differences were detectable
between SN (SNc and SNr) and cerebellum [CB, stratum
granulosum and stratum pukinjense; F(3,1) = 2.25, p < 0.0001]
revealing a significantly lower number of PK-resistant GCIs
in CB compared to SN (Figure 5). In parallel, no significant
differences in the optical density of nα-syn and pα-syn was
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FIGURE 2 | Effects of anle138b treatment on motor behavior. (A) Horizontal open-field activity showed no significant differences comparing vehicle- and
anle138b-treated PLP-α-syn mice. (B) Vertical activity (rearing) in an open-field arena did not improve significantly upon anle138b administration as compared to
vehicle treatment in PLP-α-syn mice. (C) Mice treated with anle138b showed a decreased variability of the percentage regarding the stride length coefficient of
variation (CV) in both hindlimbs compared to the vehicle group using stride length analysis. (D) PLP-α-syn mice treated with anle138b revealed a slight improvement of
grip strength compared to vehicle-treated mice, yet no statistical significance was reached. Data are presented as mean ± SEM. PLP-α-syn mice treated with vehicle
n = 10, treated with anle138b n = 8. Data were analyzed by two-way ANOVA with post-hoc Bonferroni’s test in (C). Unpaired t-test was used for the comparison of
the two groups (A, B, D).
determined between vehicle- and anle138b-treated mice in SN
and CB (Figure 6). No region-specific differences regarding the
optical density of nα-syn were found [F(3,1) = 0.6781, p =
0.0841; Figure 6A], but the optical density of pα-syn revealed
weaker signal in Stratum purkinjense compared to SN [F(3,1) =
5.005, p < 0.0001; Figure 6B].
DISCUSSION
As MSA is a fatal primary oligodendrogliopathy associated
with GCIs and selective multisystem neurodegeneration novel
therapeutic drugs that attenuate brain pathology are of great
importance. In the current study we investigated for the first
time the effect of the novel aggregation inhibitor anle138b on
behavioral outcome, neurodegeneration and α-syn aggregates in
MSA mice exposed to mitochondrial inhibition. We observed
improvement of stride length variability in anle138b treated
MSA mice. However, there were no significant effects on loss of
dopaminergic neurons or Purkinje cells and on GCI density in
SN and CB.
Promising results exist regarding the reduction of
neurodegeneration and pathological deposition of α-syn in
different PD mouse models (rotenone, MPTP, and neuronal
overexpression of α-syn) upon anle138b administration (Wagner
et al., 2013; Levin et al., 2014). After oral administration, anle138b
was shown to have a good bioavailability and blood-brain barrier
penetration without toxicity, to ameliorate motor dysfunction,
to block dopaminergic cell death, to interfere directly with the
pathological aggregation of α-syn in vitro and in vivo as well
as to prolong survival even in late-stage treatment (Wagner
et al., 2013). In the MSA model applied in the current study,
IP administration of 3-NP in transgenic PLP-α-syn mice leads
to profound behavioral motor impairment as indicated by
the motor score, open-field behavior, pole test performance,
and stride length (Stefanova et al., 2005). In agreement with
the findings of Wagner et al. (2013) we demonstrated a mild
motor improvement in the MSA mouse including significantly
reduced stride length variability linked to anle138b treatment.
Additionally, we observed a numeric but not significant
amelioration of beam walking and pole test performance
suggesting a tendency to an improved motor function and
coordination. Horizontal and rearing open-field behavior is
impaired by the effect of 3-NP treatment as shown before
(Stefanova et al., 2005), yet anle138b could not ameliorate
open field behavior in this experimental setup. We did not
find a significant improvement in the motor score of anle138b-
treated compared to vehicle-treated mice. As the motor score
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FIGURE 3 | Effects of anle138b treatment on motor behavior. Beam walking performance showed a numeric improvement regarding beam walking time (A) and
slips (B) in anle138b-treated mice compared to vehicle-treated mice. Furthermore, mice treated with anle138b presented with mild ameliorated behavior in the pole
test when measuring T-total (C) and T-turn (D) time compared to the vehicle group. However, no statistical significance was reached in any of these tests. Data are
presented as mean ± SEM. PLP-α-syn mice treated with vehicle n = 10, treated with anle138b n = 8. Unpaired t-test was used for the comparison of the two groups.
estimates a variety of changes regarding the motor phenotype of
mice, including hindlimb clasping, general locomotor activity,
hindlimb dystonia, truncal dystonia, and postural challenge
response (Fernagut et al., 2002), the scale might be too broad
to pick up mild improvement in the anle138b group compared
to the vehicle group. The mild improvement in motor deficits
of MSA mice treated with anle138b is underlined by the
neuropathological findings. As expected, treatment with 3-NP
caused a profound loss of TH-immunoreactive neurons in
SN and Purkinje cells in the CB in PLP-α-syn mice as shown
previously (Stefanova et al., 2005). In contrast to the rescue of
dopaminergic neurons in the SN in a sub-acute MPTP PDmodel
treated with anle138b (Wagner et al., 2013), we did not observe
a rescue of dopaminergic neurons, or Purkinje neurons upon
treatment with the aggregation inhibitor anle138b in the 3-NP
challenged PLP-α-syn mouse model. Furthermore, the amount
of pathological α-syn aggregates in the brain of a PD mouse
model overexpressing α-syn under a neuronal promoter was
strongly reduced by anle138b (Wagner et al., 2013). In our study,
we were not able to detect a decrease of α-syn aggregates in SN
and CB in anle138b treated PLP-α-syn mice. The amount of
pα-syn and nα-syn did not change when comparing the anle138b
and the vehicle group. However, at this stage we cannot exclude
effects of anle138b treatment on α-syn oligomers that has not
been assessed in this experiment.
One reason for the limited improvement in the current
study compared to earlier studies, could be that the compound
anle138b was either tested in synucleinopathy models created
with toxins OR neuronal overexpression of α-syn, but never
in a dual-hit mouse model (Wagner et al., 2013). In the
mouse model used in this study, the overexpression of α-syn in
oligodendrocytes combined with 3-NP-induced oxidative stress
results in severe full-blown MSA-like neuropathology (Stefanova
et al., 2005) which might necessitate the application of higher
doses of anle138b to counteract. Furthermore, in the previously
reported PD models, rotenone and MPTP act via effects on α-
syn aggregation in neurons to induce dopaminergic loss that can
be rescued by anle138b (Wagner et al., 2013; Levin et al., 2014),
while it may be speculated that 3-NP and oligodendroglial α-syn
aggregation in the MSA model trigger neuronal loss by different
mechanisms (not involving neuronal α-syn accumulation during
3-NP challenge) which may have led to the failure of anle138b to
protect the degenerating neurons in this mouse model.
Of note, we were not able to identify changes in α-syn
inclusion bodies in oligodendrocytes in the MSA model after 1
month of treatment with anle138b, although the drug has been
shown previously to counteract α-syn aggregation. As already
mentioned we cannot exclude that the duration and the dose of
the therapy in this experiment have been insufficient to provide
measurable changes in the GCI density and further studies will be
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FIGURE 4 | Impact of anle138b on dopaminergic and Purkinje neuronal
cells. A loss of dopaminergic neurons (A) and Purkinje cells (B) was induced
with the administration of 3-NP to PLP-α-syn mice compared to neuronal
numbers in PLP-α-syn mice as previously shown (Stefanova et al., 2005).
Administration of anle138b did not lead to the rescue of dopaminergic neurons
(scale bar 100µm) (A) as well as Purkinje neurons (scale bar 25µm) (B). Data
are presented as mean ± SEM. PLP-α-syn mice treated with vehicle n = 10,
treated with anle138b n = 8. Unpaired t-test was used for the comparison of
the two groups.
needed to address this issue as well as potential effects on α-syn
oligomers. Furthermore, in a recent study, 3-NP was shown to
impair the autophagic flux in oligodendroglial cells treated with
exogenously added α-syn in vitro, inducing increased number
and size of α-syn aggregates (Pukass et al., 2015). The unchanged
amount of α-syn aggregates in our PLP-α-syn mouse after
treatment with anle138b might indicate a defective autophagic
pathway after 3-NP intoxication in oligodendroglial cells in
the mouse model of the present study. Therefore, investigating
the therapeutic properties of anle138b in the PLP-α-syn mouse
model without additional oxidative stress is likely to represent a
more relevant approach for targeting α-syn aggregation in MSA
(Stefanova and Wenning, 2015).
Comparing human PD to MSA, the latter seems to be the
more progressive neurodegenerative disease with a fatal outcome
after ∼9 years whereas PD patients have a better prognosis
(Schrag et al., 2008; Lipp et al., 2009). In PD α-syn-positive
inclusions occur predominantly in neurons whereas in MSA
oligodendroglial α-syn inclusions are more common (Bruck
et al., 2015). The mechanism of the development of Lewy bodies
(LBs) in PD and GCIs in MSA has not been resolved by now.
Differences in the formation, distribution and impact of GCIs
in MSA vs. LBs in PD (Del Tredici and Braak, 2015) cannot
be excluded to contribute to potential differences in the effects
of anle138b. The differences in pathology (oligodendroglial
vs. neuronal inclusions) indicate diverging molecular pathways
FIGURE 5 | Anle138b showed no effect on numbers of PK-resistant
GCIs in PLP-α-syn mice. No reduction in the number of PK-resistant GCIs
was observed after administration of anle138b in 3-NP-treated PLP-α-syn
mice compared to the vehicle group. Neither in SN (SNc, SNr) nor in the CB
[Stratum granulosum (Str gran) and purkinjense (Str purk)] a reduced number
of PK-resistant GCIs was noted as a result of anle 138b treatment.
Region-specific differences were found with a significant lower number of
PK-resistant GCIs in the CB compared to the SN [F(3,1)= 2.25, p < 0.0001]
but these remained independent of the therapy. Scale bar 30µm. Data are
presented as mean ± SEM. PLP-α-syn mice treated with vehicle n = 10,
treated with anle138b n = 8. Data were analyzed by two-way ANOVA with
post-hoc Bonferroni’s test.
and latest findings show that different α-syn conformations
(oligomers, ribbons, fibrils; Peelaerts et al., 2015) or α-syn strains
(Prusiner et al., 2015; Woerman et al., 2015) might exist and act
differently to induce different disease patterns, suggesting that
a compound effective in PD may be less efficient in the same
dose in MSA. We cannot exclude, however, that the oxidative
stress induced by 3-NP treatment dominates the phenotype of
the mice and since anle138b does not have antioxidant effects it
cannot rescue this aspect. Indeed, nitration and phosphorylation
of α-syn were not changed by anle138b as expected.
In conclusion, we here report for the first time the effects
of the new aggregation inhibitor anle138b in a MSA mouse
model combining oligodendroglial α-syn overexpression with 3-
NP-induced oxidative stress. Taken together, the data suggest
that anle138b induced some improvement of motor impairment
supporting further development of the compound for MSA.
However, no significant protection of neuronal cells or reduction
of oligodendroglial α-syn aggregation was found. Advanced
MSA pathology reproduced in the dual-hit mouse model might
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FIGURE 6 | Effects of anle138b on nitrated and phosphorylated α-syn species in PLP-α-syn mice. The relative optical density (ROD) of nitrated α-syn
measured in the SN (SNc, SNr) and CB [Stratum granulosum (Str gran) and purkinjense (Str purk)] did not reveal any significant differences between
anle138b-compared to vehicle-treated PLP-α-syn mice. Moreover no region-specific differences were found [F(3,1) = 0.6781, p = 0.0841] (A). Furthermore, no
differences between the two treatment groups were found regarding the ROD of phosphorylated α-syn-species in SN and CB. ROD values in stratum purkinjense were
lower compared to the other regions investigated [F(3,1) = 5.005, p < 0.0001] but still independent of the anle138b treatment (B). Scale bar 25µm. Data are presented
as mean ± SEM. PLP-α-syn mice treated with vehicle n = 10, treated with anle138b n = 8. Data were analyzed by two-way ANOVA with post-hoc Bonferroni’s test.
have been too severe to permit significant neuroprotection
with anle138b treatment in the applied dose and duration.
Furthermore, interference between oxidative stress and clearance
mechanisms of α-syn may have masked the effects of anle138b
treatment on oligodendroglial α-syn aggregation in the double-
hit model of MSA. Future studies will need to address all these
issues to resolve the efficacy of anle138b for the therapy of MSA.
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